Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Corbus Pharmaceuticals Holdings (CRBP) Enterprise Value (2016 - 2026)

Corbus Pharmaceuticals Holdings has reported Enterprise Value over the past 10 years, most recently at -$9.9 million for Q4 2023.

  • For Q4 2023, Enterprise Value fell 147.32% year-over-year to -$9.9 million; the TTM value through Dec 2023 reached -$9.9 million, down 147.32%, while the annual FY2023 figure was -$9.9 million, 147.32% down from the prior year.
  • Enterprise Value for Q4 2023 was -$9.9 million at Corbus Pharmaceuticals Holdings, up from -$19.5 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$1.6 million in Q1 2020 and troughed at -$102.6 million in Q2 2021.
  • A 5-year average of -$46.4 million and a median of -$40.8 million in 2021 define the central range for Enterprise Value.
  • Biggest five-year swings in Enterprise Value: crashed 4820.51% in 2019 and later surged 98.24% in 2020.
  • Year by year, Enterprise Value stood at -$31.7 million in 2019, then tumbled by 170.2% to -$85.8 million in 2020, then fell by 5.96% to -$90.9 million in 2021, then soared by 95.6% to -$4.0 million in 2022, then crashed by 147.32% to -$9.9 million in 2023.
  • Business Quant data shows Enterprise Value for CRBP at -$9.9 million in Q4 2023, -$19.5 million in Q3 2023, and -$34.8 million in Q2 2023.